Professor Drew completed his PhD through Monash University and then undertook post-doctoral studies as an NHMRC CJ Martin Fellow at the David Geffen School of Medicine at UCLA, USA. Returning from the USA in 2013 to the Baker Institute, he established his own research program and became lab Head in 2017 of the Molecular Metabolism and Ageing Laboratory. He is a Baker Institute Fellow, a past Level II National Heart Foundation Future Leader Fellow, and now an NHMRC Senior Research Fellow (L1 Investigator). His lab has been successful in attracting >$13M in competitive research funding as a chief investigator including grants from the NHMRC, National Heart Foundation and Diabetes Australia Research Program.

Prof Drew also co-leads the Cardiometabolic Disease and Obesity Program and manages the in vivo CRISPR Validation and Metabolic Phenotyping Platforms at the Baker Institute, and also chairs the Alfred Research Alliance PAC Users Committee. He leads a research team of approximately 15 staff and students that engages in cutting edge technologies and systems genetics to examine the molecular underpinnings of cellular and tissue energy metabolism, with a focus on identifying pathways with therapeutic potential to treat cardiometabolic disorders.

He has established ties and collaborations with industry partners and many academic institutions nationally and internationally, with his work being published in leading general and specialist journals including Nature, Cell Metabolism, Science Transl Med, Eur Heart Journal, Circulation, Molecular Metab, PNAS and Diabetes.